ModifiedCignaPolicy IP0549

Complement Inhibitors - Eculizumab Products

Defines prior authorization, coverage criteria, dosing, and conditions not covered for eculizumab products (Soliris and biosimilars) for Cigna-administered health plans; applies to providers requesting coverage for listed indications.

Policy Summary

PayerCigna

PolicyComplement Inhibitors - Eculizumab Products

Policy CodePolicy IP0549

Change TypeMaterial updates to concomitant-use rules, HCPCS codes, dosing, age and duration criteria

Effective Date

Next Review Date

Key ActionSubmit prior authorization with required documentation (diagnostic confirmation and prescriber specialty) for eculizumab requests.

SourceLink

POLICY UPDATE CHANGES

Updated Conditions Not Covered language to clarify concomitant use rules, including allowance for a 4-week overlap when switching from Soliris to Empaveli and specifying exceptions for Voydeya.

New HCPCS code J1299 (Injection, eculizumab, 2 mg) was added effective 4/1/2025 and Q5151/Q5152 biosimilar codes were added.

Approval duration for atypical hemolytic uremic syndrome was extended from 6 months to 1 year and diagnostic/dosing/documentation requirements were updated.

Generalized myasthenia gravis age requirement changed to ≥6 years and MGFA/ADL scoring requirement now applies only to patients ≥18 years.

4FDA indications

Prior authorizationCoverage requirement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Eculizumab Products

Atypical Hemolytic Uremic Syndrome (aHUS) - FDA Indication

Approve for 1 year if the patient meets BOTH of the following (A and B):

aHUS criteria: A) Patient does not have Shiga toxin Escherichia coli-related hemolytic uremic syndrome; AND B) The medication is prescribed by or in consultation with a nephrologist.

Dosing specified for adult and pediatric age/weight bands.

aHUS Dosing

Approve ONE of the following (A or B):

Adult dosing: Patient ≥ 18 years: 900 mg weekly for the first 4 weeks, followed by 1,200 mg for the fifth dose 1 week later, and then 1,200 mg every 2 weeks thereafter.age >= 18

IV infusion.

Pediatric dosing: Patient < 18 years: weight-based dosing (5 kg to <10 kg; 10 kg to <20 kg; 20 kg to <30 kg; 30 kg to <40 kg; >=40 kg) with induction and maintenance schedules per weight band (see policy for exact mg and intervals).age < 18 and weight bands

IV infusion; see policy for exact mg and intervals.

Generalized Myasthenia Gravis (gMG) - FDA Indication

Approve for the duration noted if the patient meets ONE of the following (A or B):

Initial Therapy (approve 6 months): Patient is ≥ 6 years AND (if ≥ 18: MGFA class II-IV AND MG-ADL score ≥ 6) AND confirmed anti-acetylcholine receptor antibody-positive generalized myasthenia gravis [documentation required] AND patient previously received or is currently receiving pyridostigmine or had inadequate efficacy/contraindication/intolerance to it AND patient previously received or is currently receiving two different immunosuppressant therapies for ≥ 1 year or had inadequate efficacy/contraindication/intolerance to two immunosuppressants AND evidence of unresolved symptoms of gMG AND medication prescribed by or in consultation with a neurologist.age >=6; if >=18 additional thresholds

Examples of immunosuppressants listed in policy; approve initial therapy for 6 months.

Continuation Therapy (currently receiving): Patient is ≥ 6 years AND according to the prescriber the patient is continuing to derive benefit from eculizumab AND medication is prescribed by or in consultation with a neurologist (approve for 1 year).age >=6

Examples of benefit include reductions in exacerbations and improvements in speech, swallowing, mobility, and respiratory function.

gMG Dosing

Dosing — initial and continuation by age/weight bands

Adult initial dosing: >=18 years: 900 mg weekly x4, then 1,200 mg at week 5, then 1,200 mg every 2 weeks.age >=18

IV infusion.

Pediatric initial dosing: <18 years: weight-based induction schedules using five weight bands (5 kg to <10 kg; 10 kg to <20 kg; 20 kg to <30 kg; 30 kg to <40 kg; >=40 kg) with specified mg and intervals per band.age <18 and weight bands

See policy for exact mg and intervals.

Continuation dosing: >=18 years: 1,200 mg every 2 weeks; <18 years: weight-based maintenance dosing per bands (see policy for exact mg per band).continuation

Neuromyelitis Optica Spectrum Disorder (NMOSD) - FDA Indication

Approve for 1 year if the patient meets ONE of the following (A or B):

Initial Therapy (approve 1 year): Patient is ≥ 18 years AND diagnosis confirmed by positive anti-aquaporin-4 (AQP4) antibody [documentation required] AND medication prescribed by or in consultation with a neurologist.age >=18 and positive anti-AQP4

Dosing for NMOSD: 900 mg weekly x4, then 1,200 mg at week 5, then 1,200 mg every 2 weeks.

Continuation (currently receiving): Patient is ≥ 18 years AND diagnosis confirmed by positive anti-AQP4 antibody AND prescriber documents clinical benefit from eculizumab AND medication prescribed by or in consultation with a neurologist (approve 1 year).age >=18

Continuation dosing: 1,200 mg every 2 weeks.

Paroxysmal Nocturnal Hemoglobinuria (PNH) - FDA Indication

Approve if the patient meets ONE of the following (A or B):

Initial Therapy (approve 6 months): Patient is ≥ 18 years AND diagnosis confirmed by peripheral blood flow cytometry showing absence or deficiency of GPI-anchored proteins on at least two cell lineages [documentation required] AND medication prescribed by or in consultation with a hematologist.age >=18 and flow cytometry confirmation

PNH initial dosing: 600 mg weekly x4, then 900 mg at week 5, then 900 mg every 2 weeks.

Continuation (currently receiving): Patient is ≥ 18 years AND according to the prescriber the patient is continuing to derive benefit from eculizumab (examples: stabilization of hemoglobin, decreased transfusion requirements, reductions in hemolysis, improved FACIT-Fatigue) AND medication prescribed by or in consultation with a hematologist (approve 1 year).age >=18

Continuation dosing: 900 mg every 2 weeks.

Concomitant Use Restrictions

Concomitant use and indication-specific updates

Concomitant use - general rule: There is no evidence to support concomitant use of Soliris with another complement inhibitor (examples: Fabhalta, PiaSky, Ultomiris), with a rituximab product, a neonatal Fc receptor blocker, or Zilbrysq.

Exception: Voydeya (danicopan) is allowed; when switching from Soliris to Empaveli, a 4-week overlap of both therapies is permitted to reduce hemolysis risk, after which Soliris should be discontinued.

Eculizumab products used for indications or combinations not specified in this policy are considered not medically necessary. The policy explicitly lists concomitant use with Empaveli beyond a planned transition overlap as not covered: Concomitant use with Empaveli > 4 weeks is not recommended; when switching from eculizumab to Empaveli a 4-week overlap of both therapies is permitted to reduce hemolysis risk, after which eculizumab must be discontinued. Other off-label or unapproved concurrent uses are also categorized as not medically necessary.

The policy explicitly states that concomitant use of eculizumab with Enspryng (satralizumab) or Uplizna (inebilizumab) is not supported by the evidence and is therefore considered a condition not covered. This language replaces prior, more specific condition listings and clarifies that combinations with these agents are not permitted under the policy.

Requests for concomitant administration of eculizumab with other listed agents are considered not medically necessary due to lack of evidence supporting combination therapy. The policy names examples of excluded complement inhibitors (e.g., Fabhalta, PiaSky, Ultomiris) and also excludes combinations with rituximab products, neonatal Fc receptor blockers, and Zilbrysq, with the single exception of Voydeya (danicopan) which is permitted.

Use of eculizumab concurrently with Enspryng or Uplizna, and with most other complement inhibitors, is considered unsupported by available evidence and therefore not covered. The policy reiterates that there is no evidence to support concomitant use of Soliris (eculizumab) with other complement inhibitors except for Voydeya; concomitant use with Enspryng or Uplizna is specifically listed as not covered.

Billing and Code References

Coding notesmixed

No codes listed

HCPCS CodesHCPCS

J1299	Injection, eculizumab, 2 mg (Code effective 4/1/2025)
J1300	Injection, eculizumab, 10 mg (Code effective until 3/31/2025)
Q5151	Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg (Code effective 4/1/2025)
Q5152	Injection, eculizumab-aeeb (bkemv), biosimilar, 2 mg (Code effective 4/1/2025)

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior Authorization is required for benefit coverage of eculizumab. Approval is recommended for individuals who meet the Criteria and Dosing for the listed indications. Approvals are provided for the duration noted in the policy; extended approvals may be granted if the patient continues to meet the Criteria and Dosing. Eculizumab must be prescribed by or in consultation with a physician who specializes in the condition being treated.

All approvals are provided for the duration noted in the policy. When dosing intervals are provided in months, 1 month = 30 days.
Requests for doses outside of established dosing will be considered on a case-by-case basis by a clinician (e.g., Medical Director or Pharmacist).

Documentation Required

Documentation Requirements

Documentation is required where noted in the criteria as [documentation required]. Documentation may include, but is not limited to, chart notes, laboratory test results, and claims records. Documentation requirements and dosing have been updated throughout the policy; ensure submitted records reflect current dosing per the prescribing information and any indication-specific documentation listed in the criteria (for example, confirmation of anti-AChR antibody for gMG or positive anti-AQP4 antibody for NMOSD).

Background

Eculizumab is a complement C5 inhibitor with FDA-approved indications including atypical hemolytic uremic syndrome (aHUS), anti-AChR antibody–positive generalized myasthenia gravis (gMG), AQP4-IgG–positive neuromyelitis optica spectrum disorder (NMOSD), and paroxysmal nocturnal hemoglobinuria (PNH). The drug is distributed under a restricted access program because of a boxed warning for serious meningococcal infections and requires appropriate vaccination where clinically indicated. Clinical justification and required documentation differ by indication (for example, anti-AChR antibody confirmation for gMG, positive anti-AQP4 antibody for NMOSD, and peripheral blood flow cytometry confirmation for PNH). Prior authorization is required for benefit coverage and approvals are issued for specified durations per the criteria.

Definitions

inv-23: Atypical hemolytic uremic syndrome (aHUS)

DefinitionA subtype of hemolytic uremic syndrome caused by dysregulation of the complement system leading to thrombotic microangiopathy and endothelial damage in the renal and other microvasculature; not caused by Shiga toxin–producing E. coli.

Diagnostic distinctionShould be distinguished from typical HUS (Shiga toxin E. coli–related), for which eculizumab is not indicated.

PathophysiologyUnderlying lesions mediated by systemic thrombotic microangiopathy due to complement dysregulation.

Clinical triadCharacterized by non‑immune hemolytic anemia, thrombocytopenia, and acute renal failure.

Actionable noteEculizumab is indicated for aHUS when criteria are met (see coverage criteria); confirm non–Shiga toxin etiology prior to approval.

Policy Summary

PayerCigna

PolicyComplement Inhibitors - Eculizumab Products

Policy CodePolicy IP0549

Change TypeMaterial updates to concomitant-use rules, HCPCS codes, dosing, age and duration criteria

Effective Date

Next Review Date

Key ActionSubmit prior authorization with required documentation (diagnostic confirmation and prescriber specialty) for eculizumab requests.

SourceLink

On This Page

Denial Risk

Transition Overlap Recommendation and Concomitant Use Restrictions

When transitioning patients from Soliris (eculizumab) to Empaveli (pegcetacoplan), a 4-week overlap of both therapies is recommended to reduce the risk of hemolysis from abrupt discontinuation of Soliris; after 4 weeks, discontinue Soliris and continue Empaveli monotherapy. Concomitant use of eculizumab with another complement inhibitor is generally not recommended (exceptions and additional restrictions noted in the policy, e.g., Voydeya).

To reduce hemolysis risk when switching from Soliris to Empaveli: overlap both therapies for 4 weeks, then discontinue Soliris.
Concomitant use with other complement inhibitors (except Voydeya) is not supported; concomitant use with Enspryng or Uplizna is not supported.

DefinitionChronic autoimmune neuromuscular disease causing fluctuating skeletal muscle weakness, most commonly due to autoantibodies to the acetylcholine receptor (AChR).

Key diagnostic requirementFor eculizumab coverage the patient must be anti‑AChR antibody‑positive (documentation required).

Clinical featuresMuscle weakness that worsens with activity and improves with rest; can affect respiratory and limb muscles.

Therapy prerequisitesInitial therapy criteria require prior pyridostigmine use and typically two different immunosuppressants for ≥1 year unless intolerant or contraindicated.

Age thresholdPolicy minimum age for the gMG indication is ≥6 years; additional adult functional score requirements apply for patients ≥18 years.

inv-25: Neuromyelitis optica spectrum disorder (NMOSD)

DefinitionA rare, relapsing autoimmune disorder with optic neuritis and/or myelitis that can cause permanent vision or spinal cord damage.

Diagnostic requirementCoverage requires positive anti‑AQP4 (AQP4‑IgG) antibody confirmation with documentation for initial therapy.

Typical acute managementAcute attacks are treated with high‑dose glucocorticoids and/or apheresis; long‑term immunotherapy recommended for AQP4‑IgG‑positive cases.

Treatment options noteEculizumab is one of the first‑choice long‑term therapies for AQP4‑IgG‑positive NMOSD among several options; choice depends on disease activity, route, and patient factors.

inv-26: Paroxysmal nocturnal hemoglobinuria (PNH)

DefinitionA rare, acquired hematopoietic stem cell disorder caused by PIGA mutation leading to deficiency of GPI‑anchored proteins, resulting in hemolysis, thrombosis, and cytopenias.

Diagnostic confirmationDiagnosis should be confirmed by peripheral blood flow cytometry demonstrating absence or severe deficiency of GPI‑anchored proteins on at least two cell lineages.

Clinical consequencesLeads to hemolytic anemia, increased thrombotic risk, and peripheral blood cytopenias; supportive measures historically included transfusions and anticoagulation.

Documentation notePrior authorization requires hematologist involvement and documentation of flow cytometry results for initial therapy decisions.

inv-27: PNH diagnosis by flow cytometry

Required testPeripheral blood flow cytometry demonstrating absence or deficiency of GPI‑anchored proteins on at least two cell lineages is required to confirm PNH diagnosis.

ReasoningFlow cytometry detects loss of GPI‑anchored proteins resulting from PIGA mutation, which is the diagnostic hallmark of PNH.

DocumentationFlow cytometry results must be provided with the authorization request as specified in the policy.

Policy revision notePolicy wording was updated to explicitly state ‘on at least two cell lineages’ for flow cytometry confirmation.